In surveys where this may influence the main research question, data should also be collected with other methods reaching the oldest patients. Copyright (c) 2013 John Wiley & Sons, Ltd.”
“The family Caliscelidae is revised and listed in the Afrotropical Region and is recorded from Madagascar for the first time. Signoreta victorina gen. et sp. n., Calampocus TH-302 datasheet sphaeroides gen. et sp. n., Patamadaga pauliani

gen. et sp. n., Sphenax cuneus gen. et sp. n., Afronaso gryphus sp. n. and A. malagasicus sp. n. are described from Madagascar. Rhinoploeus iwa gen. et sp. n. is described from Zambia and Caliscelis swazi sp. n. from Republic of South Africa and Swaziland. Nubianus gen. n. is erected for Issopulex nasutus Linnavuori, 1973. Issopulex chloe

Linnavuori, 1973 is transfered to the genus check details Savanopulex Dlabola and Caliscelis eximia Stal, 1859 to the genus Chirodisca Emeljanov. Afronaso rhinarius cuneiceps Fennah, 1957 is upgraded to species level. Populonia curculioforma Dlabola, 1987 is placed in synonymy under A. rhinarius cuneiceps, Populonia hammersteini Schmidt, 1932 under Homaloplasis curvata Melichar, 1908, Ugandana fennahi Dlabola, 1987 under Afronaso bayoni Schmidt, 1911, and Caliscelis dreyfus Fernando, 1957 under Caliscelis eximia Stal, 1859. New faunistic records are proposed. The possible Gondwanan origin and monophyly of the Caliscelidae are briefly discussed.”
“Bevacizumab is a monoclonal antibody directed against Vascular Endothelial Growth Factor (VEGF). Evidence about its efficacy in addition to first-line chemotherapy in non-small-cell-lung-cancer (NSCLC) has been produced by two large randomized phase III clinical trials (ECOG 4599 and AVAiL), conducted

in a clinically selected Androgen Receptor Antagonist cell line population with non-squamous histology and without major risk factors for bleeding. In the ECOG 4599 trial, the addition of bevacizumab (15 mg/kg) to carboplatin plus paclitaxel produced a statistically significant and clinically relevant improvement in overall survival (OS), that was the primary endpoint of the trial (12.3 months vs 10.3 months, HR 0.79; p=0.003). Furthermore, patients receiving bevacizumab showed a significant improvement in progression-free survival (PFS) and in objective response rates. Treatment with bevacizumab was well tolerated by the majority of patients, but was still associated with increased risk of clinically significant bleeding (4.4% vs 0.7%, p<0.001). In the AVAiL trial the addition of bevacizumab (at the dose of 7.5 and 15 mg/kg) to cisplatin plus gemcitabine produced a small improvement in PFS, but no differences in OS.